Efficacy and safety of dolutegravir and rilpivirine dual therapy as a simplification strategy: a cohort study-Reference-Cited by-同舟云学术

Efficacy and safety of dolutegravir and rilpivirine dual therapy as a simplification strategy: a cohort study

Published:2017-04-26 Issue:9 Volume:18 Page:704-708
ISSN:1464-2662
Container-title:HIV Medicine
language:en
Short-container-title:HIV Med

Author:

Gantner P¹,Cuzin L²³⁴,Allavena C⁵,Cabie A⁶,Pugliese P⁷,Valantin M-A⁸⁹,Bani-Sadr F¹⁰,Joly V¹¹,Ferry T¹²,Poizot-Martin I¹³,Garraffo R¹⁴,Peytavin G¹⁵¹⁶,Fafi-Kremer S¹,Rey D¹⁷,

Affiliation:

1. Virology Laboratory; Hôpitaux Universitaires de Strasbourg; Strasbourg France

2. INSERM; UMR 1027; Toulouse France

3. Université de Toulouse III; Toulouse France

4. CHU Toulouse; COREVIH Toulouse; Toulouse France

5. Infectious Diseases Department; CHU de Nantes; Nantes France

6. Infectious Diseases Department; CHU de Fort-de-France; Martinique France

7. Infectious Diseases Department; CHU de Nice; Nice France

8. Infectious Diseases Department; APHP Hôpital Pitié Salpêtrière; Paris France

9. Institut Pierre Louis d'épidémiologie et de Santé Publique (UMRS 1136); UPMC Univ Paris 06; INSERM; Sorbonne Universités; Paris France

10. Infectious Diseases Department; CHU de Reims; Reims France

11. Infectious Diseases Department; APHP Hôpital Bichat; Paris France

12. Infectious Diseases Department; Hospices civils de Lyon; Lyon France

13. APHM Hôpital Sainte-Marguerite; Immuno-Hematology Clinic; Aix-Marseille University; Marseille France

14. Pharmacology Laboratory; CHU de Nice; Nice France

15. AP-HP; Pharmacology Laboratory; Hôpital Bichat-Claude Bernard; Paris France

16. IAME; UMR 1137; Sorbonne Paris Cité, INSERM; Université Paris Diderot; Paris France

17. Le Trait d'Union; HIV-Infection Care Center; Hôpitaux Universitaires de Strasbourg; Strasbourg France

Publisher

Wiley

Subject

Pharmacology (medical),Infectious Diseases,Health Policy

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/hiv.12506/fullpdf

Reference20 articles.

1. Cross-sectional comparison of the prevalence of age-associated comorbidities and their risk factors between HIV-infected and uninfected individuals: the AGEhIV cohort study;Schouten;Clin Infect Dis,2014

2. HIV and aging: state of knowledge and areas of critical need for research. A report to the NIH Office of AIDS Research by the HIV and Aging Working Group;High;J Acquir Immune Defic Syndr,2012

3. Dual therapy treatment strategies for the management of patients infected with HIV: a systematic review of current evidence in ARV-naive or ARV-experienced, Virologically Suppressed Patients;Baril;PLoS One,2016

4. Once-daily dolutegravir versus twice-daily raltegravir in antiretroviral-naive adults with HIV-1 infection (SPRING-2 study): 96 week results from a randomised, double-blind, non-inferiority trial;Raffi;Lancet Infect Dis,2013

5. Dolutegravir versus raltegravir in antiretroviral-experienced, integrase-inhibitor-naive adults with HIV: week 48 results from the randomised, double-blind, non-inferiority SAILING study;Cahn;Lancet,2013

Cited by 46 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Prevalence of Emergent Dolutegravir Resistance Mutations in People Living with HIV: A Rapid Scoping Review;Viruses;2024-03-04

2. Risk of Emergent Dolutegravir Resistance Mutations In People Living With HIV: A Rapid Scoping Review;2024-01-07

3. Therapeutic drug monitoring and virological response at week 48 in a cohort of HIV‐1‐infected patients switching to dolutegravir/rilpivirine dual maintenance therapy (ANRS‐MIE‐BIRIDER study);British Journal of Clinical Pharmacology;2023-09-18

4. Evaluation of integrase resistance in individuals who failed a regimen containing dolutegravir in French and Italian clinical settings;Journal of Antimicrobial Chemotherapy;2023-04-24

5. Efficacy and Safety of Two-Drug Regimens with Dolutegravir plus Rilpivirine or Lamivudine in HIV-1 Virologically Suppressed People Living with HIV;Viruses;2023-04-10